Microbiome therapies as precision medicine

Developing complete microbiota ecosystem products and microbiome therapies to improve human health


Mission & Vision

Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.

Microviable’s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients’ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.


Tailored projects for pharma, biotech and food industry.


Next generation biotherapeutics development and probiotics.


Unravel the composition and functionality of the microbiome.


Store your microbiota as a biotherapeutic resource.

GutAlive® – Anaerobic

microbiome collection kit

GutAlive® is the unique microbiome collection kit that generates an anaerobic atmosphere enabling oxygen sensitive bacteria to survive, maintaining the original composition and diversity of the microbiota.

GutAlive®  maintains the bacterial viability together with DNA stability and integrity, a best in class device suitable for both anaerobic bacteria isolation and microbiome analyses.

GutAlive® is a suitable device for microbiome sampling with no limitation on DNA quality and quantity for NGS technologies and microbiome analyses through 16s rRNA sequencing or metagenomics.

The use of GutAlive®  to collect and transport the stool sample at room temperatura enables downstream isolation of a wide diversity of bacterial genera, including anaerobic bacteria.

GutAlive® guarantees sample stability over 72 hours, without refrigeration, to ensure the proper atmosphere conditions for sample collection and transport to the laboratory.

GutAlive® is a unique on its kind device with a high-capacity container that can fit up to 120 grams of stool sample enabling various downstream applications like fecal microbiota transplant (FMT), bacterial isolation and microbiome analysis.

GutAlive® enables to standardize sample collection and transport, without refrigeration, minimizing variations among procedures and maintaining the original composition of the microbiome, key items for downstream analysis and applications especially for microbiota-based therapeutics and diagnostics.


You can follow the latest news of MicroViable in this section


    Name *

    Email *

    Subject *

    Comments *

    Get in touch with us for any questions using the following contact form.

      C/ Los Prados, 166
      33203 – Gijón – Spain
      C/ Fernando Bongera s/n
      Edificio Severo Ochoa
      Campus de El Cristo Planta – 1
      33006 – Oviedo – Asturias – Spain

    Go to Top